SCR

[BigSully1]

April '06 IPO

Simcere Pharmaceutical Group.
No 699-18 Xuan Wu Avenue
Xuan Wu District
Nanjing,  210042
China - Map
Phone: 86 25 8556 6666
Fax: 86 25 8547 1729
Web Site: http://www.simcere.com

DETAILS   
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 1,838


BUSINESS SUMMARY   
Simcere Pharmaceutical Group, through its subsidiaries, engages in the manufacture and supply of branded generic pharmaceuticals in the People's Republic of China. It manufactures and sells 35 pharmaceutical products and distributes 3 additional pharmaceuticals under its brand names. The company's products include antibiotics, an anti-stroke medication, anti-inflammatory pain relievers, an anti-cancer medication, and other pharmaceuticals. Its principal branded generic pharmaceutical products comprise edaravone injection under the name Bicun; amoxicillin capsules, dispersible tablets, granules, and injection under the brand Zailin; amoxicillin with clavulanate potassium granules, tablets, and injection under the name Anqi; diclofenac sodium sustained-release capsules and gelatin under the brand Yingtaiqing; and smectite powder under the name Biqi. The company distributes prescription pharmaceuticals manufactured by independent third parties, including generic diclofenac sodium sustained-release capsules under the brand Yingtaiqing, generic alfacalcidol soft capsules under the name Faneng, and generic lentinan injection under the brand Yineng. As of March 20, 2007, it also had 12 product candidates in various stages of development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nasal allergies, and nausea and vomiting associated with chemotherapy. Simcere Pharmaceutical Group markets and sells its products to approximately 900 regional pharmaceutical distributors, who in turn sell these products to local distributors, hospitals, and retail pharmacies. The company was founded in 1995 and is headquartered in Nanjing, the People's Republic of China.

[BigSully1]

http://seekingalpha.com/article/67221-simcere-pharmaceutical-gains-on-strong-earnings

http://seekingalpha.com/article/67216-simcere-books-solid-2007

[BigSully1]

Hasn't moved much yet, but strong volume last few days.

[BigSully1]

volume picking up again

[BigSully1]

A liittle buying pressure building up, anyway it's the highest close in 3 months. Still holding all with anticipation of appreciation. HeHe, that's a bit  of a tongue twister.
ER May 6
-------------------------------------------------

Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
Tuesday April 22, 2:31 am ET


NANJING, China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical Group (NYSE: SCR; ''Simcere''), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced that it has signed a definitive agreement to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical Co. Ltd. for a total cash consideration of RMB64.82 million (US $9.26 million). This transaction is consistent with Simcere's strategy to focus on first-to-market and innovative new drugs and expand its anti-cancer product portfolio.

Zhong Ren Pharmaceutical is a Chinese drug manufacturer specializing in the production of sustained release anti-tumor implants. Its key product SinoFuan (fluorouracil implant), is proven to effectively inhibit the growth of tumors, and is the only sustained release anti-tumor implant approved by the State Food and Drug Administration (SFDA). SinoFuan is commonly used to treat cancers of the digestive tract and is a favored choice for use during surgery. No similar product exists on the Chinese market today. Distribution of SinoFuan through Simcere's established marketing channels will enhance Simcere's offerings in the anti-cancer drug market, benefit cancer patients across China and create greater value for Simcere shareholders.

------------------------------------------------

[BigSully1]

closed at the H.O.D.